We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
High dosage rifaximin for the treatment of small intestinal bacterial overgrowth.
- Authors
SCARPELLINI, E.; GABRIELLI, M.; LAURITANO, C. E.; LUPASCU, A.; MERRA, G.; CAMMAROTA, G.; CAZZATO, I. A.; GASBARRINI, G.; GASBARRINI, A.
- Abstract
Background Rifaximin is a broad spectrum non-absorbable antibiotic used for treatment of small intestinal bacterial overgrowth. Doses of 1200 mg/day showed a decontamination rate of 60% with low side-effects incidence. Aims To assess efficacy, safety and tolerability of rifaximin 1600 mg with respect to 1200 mg/day for small intestinal bacterial overgrowth treatment. Methods Eighty consecutive small intestinal bacterial overgrowth patients were enrolled. Diagnosis of small intestinal bacterial overgrowth based the clinical history and positivity to H2/CH4 glucose breath test. Patients were randomized in two 7-day treatment groups: rifaximin 1600 mg (group 1); rifaximin 1200 mg (group 2). Glucose breath test was reassessed 1 month after. Compliance and side-effect incidence were also evaluated. Results One drop-out was observed in group 1 and two in group 2. Glucose breath test normalization rate was significantly higher in group 1 with respect to group 2 both in intention-to-treat (80% vs. 58%; P < 0.05) and per protocol analysis (82% vs. 61%; P < 0.05). No significant differences in patient compliance and incidence of side effects were found between groups. Conclusions Rifaximin 1600 mg/day showed a significantly higher efficacy for small intestinal bacterial overgrowth treatment with respect to 1200 mg with similar compliance and side-effect profile.
- Subjects
ANTIDIARRHEALS; VIRAL diarrhea; BACTERIAL growth; SMALL intestine; BREATH tests; ANTIBIOTICS assay
- Publication
Alimentary Pharmacology & Therapeutics, 2007, Vol 25, Issue 7, p781
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/j.1365-2036.2007.03259.x